Spring Bank Pharmaceuticals was founded in 2002. From its inception, the company has sought to apply its small molecule nucleic acid hybrid (SMNH) chemistry platform toward the discovery and development of novel drugs, and we have made significant progress over the past decade optimizing our SMNH compounds with favorable drug attributes. By making specific structural modifications to SMHN compounds, we enable them to bind to targets in the diseased tissues with high affinity and selectivity. This work has culminated in strong preclinical evidence of safety and activity as well as the first SMNH to go into human clinical studies in early 2013.